资讯
The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...
RSV is the leading cause of hospitalization in US infants, and in August 2023, the CDC’s vaccine advisory group recommended ...
With the approach of fall likely bringing the usual uptick in respiratory illness, the provincial government is boosting its ...
A successful example of these technologies coming together is Sanofi and AstraZeneca’s Beyfortus (nirsevimab-alip), an anti-RSV monoclonal antibody approved for the prevention of RSV in infants.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果